Jasper Therapeutics, Inc. (JSPR) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Jasper Therapeutics, Inc. has no measured co-movers clearing our correlation floor, so only its SEC classification is shown.
SIC 2836, Biological Products, (No Diagnostic Substances), from each company's own filings. Largest first.
tall tick = annual report · 1 on record
44 managers report a position worth $5.2M between them, and 9 of them hold 80% of it.
the bull case· 1
44
managers reporting a position in thirteen f filings
13fJun 30 '26the bear case· 3
9
managers whose positions together make up four fifths of reported value
13fJun 30 '266 of 23
largest reporting managers cutting their stake in the latest quarter
13fJun 30 '26−5.74%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 10 '26 report. Not a forecast, not advice.
JSPR (Jasper Therapeutics, Inc.) has 1 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
Jasper Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
High 0.63 at 3:30 pm ET, low 0.61 at 12:00 pm ET.